Drug interaction and pharmacokinetic modeling of oxcarbazepine in Korean patients with epilepsy

Clinical Neuropharmacology

Volumn 35, Issue 1, 2012, Pages 40-44

  Park, Kyoung Jin ^a   Kim, Jung Ryul ^a   Joo, Eun Yeon ^a   Seo, Dae Won ^a   Hong, Seung Bong ^a   Ko, Jae Wook ^a   Kim, Suk Ran ^a   Huh, Wooseong ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

10 hydroxycarbazepine; drug interaction; epilepsy; oxcarbazepine; therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TOPIRAMATE; ZONISAMIDE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPONATREMIA; KOREA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEX RATIO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; PHENYTOIN; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862955001     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824150a5     Document Type: Article

References (18)

1. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023-1042. (Pubitemid 37186675)
2. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21:904-919. (Pubitemid 32747311)
3. Shorvon S. Oxcarbazepine: a review. Seizure 2000;9:75-79. (Pubitemid 30209794)
4. Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet 2008;47:767-778.
5. Kang JK, Yang HO, Park SY, et al. The pharmacokinetic interaction and therapeutic plasma concentration of oxcarbazepine. J Korean Epilepsy Soc 1999;3:200-205.
6. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(suppl 3):S10-S13. (Pubitemid 24145238)
7. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005;27:199-204. (Pubitemid 40463649)
8. Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, et al. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000;31:202-205. (Pubitemid 30392359)
9. Viola MS, Bercellini MA, Saidon P, et al. [Pharmacokinetic variability of oxcarbazepine in epileptic patients]. Medicina (B Aires) 2000;60:914-918.
10. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994;47:161-167. (Pubitemid 24314737)
11. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994;35(suppl 3):S14-S19.
12. Sallas WM, Milosavljev S, D'Souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003;74:138-149. (Pubitemid 36951811)
13. Novartis Pharmaceuticals Corporation. Trileptal\ (oxcarbazepine) prescribing information. 2009.
14. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061-1075. (Pubitemid 44631387)
15. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugsVbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276. (Pubitemid 351991390)
16. Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001;104:167-170. (Pubitemid 32831779)
17. Lin CH, Lu CH, Wang FJ, et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clin Neuropharmacol 2010;33:293-296.
18. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-1365. (Pubitemid 47063090)